GlassScriptPhysician profile
Leigh Suzanne Johnson
NPI 1609861442
$3,597.06
in general payments reported to CMS, 2019-2025
37 companies · $788 in 2025
The $788 reported for 2025 was more than what 81% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $298 · 2022: $957 · 2023: $736 · 2024: $818 · 2025: $788.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,342.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,342.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $566.35 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Teva Pharmaceuticals USA, INC. | $388.49 | 2022-2023 | Austedo, Austedo Xr |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $347.15 | 2022-2023 | |
| Alkermes, INC. | $258.47 | 2022-2023 | Aristada, Lybalvi |
| Abbvie INC. | $237.75 | 2023-2025 | |
| Lilly USA, LLC | $172.39 | 2023-2025 | Mounjaro, Zepbound, Emgality |
| Exact Sciences Corporation | $164.22 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Glaxosmithkline, LLC. | $160.93 | 2023-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Vanda Pharmaceuticals INC. | $143.90 | 2022-2025 | Fanapt, Hetlioz |
| Bayer Healthcare Pharmaceuticals INC. | $127.10 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $106.39 | 2022-2023 | Glassia, Trintellix |
| Nevro Corp. | $92.20 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $88.42 | 2022-2023 | Rexulti, Abilify Maintena |
| Neurocrine Biosciences, INC. | $84.20 | 2022-2023 | Ingrezza |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $65.48 | 2021-2025 | Xifaxan |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inogen, INC. | $63.64 | 2024-2025 | |
| Axsome Therapeutics, INC. | $57.41 | 2023-2025 | Auvelity |
| Astrazeneca Pharmaceuticals LP | $41.60 | 2023-2025 | Farxiga, Breztri |
| Biodelivery Sciences International, INC. | $41.10 | 2021 | |
| Merck Sharp & Dohme LLC | $38.23 | 2024 | Capvaxive, Gardasil 9, Gardasil |
| Si-Bone, INC. | $37.54 | 2021 | |
| Lundbeck LLC | $32.50 | 2022-2024 | Vyepti |
| Scilex Pharmaceuticals INC. | $29.91 | 2021 | |
| Indivior INC. | $27.49 | 2023 | Perseris |
| Daiichi Sankyo INC. | $22.52 | 2024 | Injectafer |
| Pfizer INC. | $22.14 | 2025 | |
| Nalu Medical, INC. | $22.06 | 2021 | |
| Boston Scientific Corporation | $21.28 | 2025 | General - Female Sui |
| Eisai INC. | $20.79 | 2024 | |
| Amgen INC. | $20.42 | 2021 | |
| Medtronic, INC. | $16.18 | 2024 | Intellis Adaptivestim |
| Janssen Pharmaceuticals, INC | $16.06 | 2023 | Spravato |
| Astellas Pharma US INC | $14.62 | 2025 | Veozah |
| Mylan Specialty L.P. | $13.75 | 2024 | Yupelri |
| Sanofi Pasteur INC. | $13.06 | 2023 | |
| Horizon Therapeutics Plc | $11.60 | 2021 | |
| Phathom Pharmaceuticals, INC. | $9.72 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leigh Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.